Effects of a 3-Week In-Hospital Body Weight Reduction Program on Cardiovascular Risk Factors, Muscle Performance, and Fatigue: A Retrospective Study in a Population of Obese Adults with or without Metabolic Syndrome.
Adolescent
Adult
Aged
Aged, 80 and over
Body Mass Index
Cardiovascular Diseases
/ complications
Cholesterol, HDL
/ blood
Fatigue
/ etiology
Female
Heart Disease Risk Factors
Hospitals
Humans
Male
Metabolic Syndrome
/ complications
Middle Aged
Muscles
Obesity
Retrospective Studies
Weight Loss
Weight Reduction Programs
Young Adult
body mass index
body weight reduction program
cardiovascular risk factors
fatigue severity score
metabolic syndrome
obesity
stair climbing test
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
21 May 2020
21 May 2020
Historique:
received:
27
04
2020
revised:
18
05
2020
accepted:
20
05
2020
entrez:
28
5
2020
pubmed:
28
5
2020
medline:
17
2
2021
Statut:
epublish
Résumé
In clinical practice, there is the diffuse conviction that obese subjects with metabolic syndrome may be more difficult to treat. The aim of the present study was that to investigate the effectiveness of a 3-week in-hospital body weight reduction program (BWRP) in a large population of obese subjects with and without metabolic syndrome ( When compared to obese subjects without metabolic syndrome, at the basal conditions, obese subjects had a poorer cardiometabolic profile, as demonstrated by higher triglycerides, TOT-cholesterol, DBP, SBP, and CHD score, and a more compromised muscle performance (evaluated by SCT), associated with more perception of fatigue (measured by FSS). Nevertheless, obese subjects with metabolic syndrome obtained more benefits from BWRP than those without metabolic syndrome for some outcomes (i.e., ΔTOT-cholesterol, ΔSBP, and ΔCHD score). Despite these differences, the BWRP-induced weight loss was similar between the two groups (i.e., ΔBMI) as well as the gain of muscle performance (i.e., ΔSCT) and the reduction of fatigue (i.e., ΔFSS). Interestingly, the potentially deleterious fall in HDL-cholesterol levels after BWRP was less evident in obese subjects with metabolic syndrome than those without metabolic syndrome. When pooling all data, the ΔCHD score was associated with age, sex, and metabolic syndrome. The remaining outcomes, such as ΔBMI, ΔFSS, and ΔSCT time, were associated with sex and age but not with metabolic syndrome. Finally, ΔBMI was positively correlated with ΔCHD score, ΔFSS, and ΔSCT time in both obese subjects without metabolic syndrome and obese subjects with metabolic syndrome. When comparing obese subjects undergoing a BWRP, metabolic syndrome is not a negative predictive factor affecting the effectiveness of this intervention in terms of weight loss, muscle performance, and psychological well-being.
Sections du résumé
BACKGROUND
BACKGROUND
In clinical practice, there is the diffuse conviction that obese subjects with metabolic syndrome may be more difficult to treat.
OBJECTIVES AND METHODS
OBJECTIVE
The aim of the present study was that to investigate the effectiveness of a 3-week in-hospital body weight reduction program (BWRP) in a large population of obese subjects with and without metabolic syndrome (
RESULTS
RESULTS
When compared to obese subjects without metabolic syndrome, at the basal conditions, obese subjects had a poorer cardiometabolic profile, as demonstrated by higher triglycerides, TOT-cholesterol, DBP, SBP, and CHD score, and a more compromised muscle performance (evaluated by SCT), associated with more perception of fatigue (measured by FSS). Nevertheless, obese subjects with metabolic syndrome obtained more benefits from BWRP than those without metabolic syndrome for some outcomes (i.e., ΔTOT-cholesterol, ΔSBP, and ΔCHD score). Despite these differences, the BWRP-induced weight loss was similar between the two groups (i.e., ΔBMI) as well as the gain of muscle performance (i.e., ΔSCT) and the reduction of fatigue (i.e., ΔFSS). Interestingly, the potentially deleterious fall in HDL-cholesterol levels after BWRP was less evident in obese subjects with metabolic syndrome than those without metabolic syndrome. When pooling all data, the ΔCHD score was associated with age, sex, and metabolic syndrome. The remaining outcomes, such as ΔBMI, ΔFSS, and ΔSCT time, were associated with sex and age but not with metabolic syndrome. Finally, ΔBMI was positively correlated with ΔCHD score, ΔFSS, and ΔSCT time in both obese subjects without metabolic syndrome and obese subjects with metabolic syndrome.
CONCLUSIONS
CONCLUSIONS
When comparing obese subjects undergoing a BWRP, metabolic syndrome is not a negative predictive factor affecting the effectiveness of this intervention in terms of weight loss, muscle performance, and psychological well-being.
Identifiants
pubmed: 32455545
pii: nu12051495
doi: 10.3390/nu12051495
pmc: PMC7284609
pii:
doi:
Substances chimiques
Cholesterol, HDL
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Prev Med. 2017 Jul;100:180-193
pubmed: 28450123
J Med Food. 2011 Apr;14(4):386-90
pubmed: 21370966
Health Qual Life Outcomes. 2013 Mar 06;11:32
pubmed: 23496886
Eat Weight Disord. 2003 Jun;8(2):107-13
pubmed: 12880187
Clin Nutr ESPEN. 2018 Dec;28:21-35
pubmed: 30390883
J Endocrinol. 2000 Sep;166(3):529-36
pubmed: 10974647
Diabetes Nutr Metab. 2003 Aug;16(4):262-5
pubmed: 14768777
Int J Obes Relat Metab Disord. 2004 Jan;28(1):91-8
pubmed: 14710170
Br Med Bull. 2011;97:169-96
pubmed: 21325341
Circulation. 1998 May 12;97(18):1837-47
pubmed: 9603539
Braz J Med Biol Res. 2017 Oct 19;50(12):e6432
pubmed: 29069229
Nutrients. 2019 May 31;11(6):
pubmed: 31159183
Eur J Endocrinol. 2011 Sep;165(3):421-7
pubmed: 21677050
Food Nutr Res. 2015 Nov 04;59:29678
pubmed: 26546790
Genes Nutr. 2009 Mar;4(1):49-57
pubmed: 19247701
Diabetes Nutr Metab. 2001 Feb;14(1):51-7
pubmed: 11345166
Curr Atheroscler Rep. 2005 Mar;7(2):95-102
pubmed: 15727723
Int J Behav Nutr Phys Act. 2013 Dec 07;10:135
pubmed: 24313992
Obes Rev. 2015 Feb;16(2):171-86
pubmed: 25494712
Nat Rev Endocrinol. 2018 Sep;14(9):513-537
pubmed: 30065268
Nutrients. 2020 Jan 13;12(1):
pubmed: 31941135
Neuromolecular Med. 2008;10(2):67-80
pubmed: 18274707
Hormones (Athens). 2018 Sep;17(3):321-331
pubmed: 30014320
Clin Nutr Res. 2015 Apr;4(2):69-75
pubmed: 25954727
Qual Life Res. 2012 Aug;21(6):925-44
pubmed: 22012025
Int J Pediatr Obes. 2010;5(1):34-42
pubmed: 19593727
Am J Med. 2014 Dec;127(12):1242.e1-10
pubmed: 25004456
Curr Hypertens Rep. 2018 May 1;20(5):39
pubmed: 29717392
Int J Mol Sci. 2019 Feb 02;20(3):
pubmed: 30717377
Diabetes Nutr Metab. 2003 Apr;16(2):88-93
pubmed: 12846447
Int J Fertil Womens Med. 1997 May-Jun;42(3):184-97
pubmed: 9222803
Diabetes Obes Metab. 2012 Jul;14(7):616-25
pubmed: 22284386
Eur J Clin Nutr. 2001 Oct;55(10):865-9
pubmed: 11593348
Best Pract Res Clin Obstet Gynaecol. 2016 Nov;37:140-151
pubmed: 26972165
J Endocrinol Invest. 2001 Jun;24(6):393-8
pubmed: 11434662
Front Cardiovasc Med. 2018 Sep 28;5:135
pubmed: 30324108
Mol Nutr Food Res. 2016 Jan;60(1):43-57
pubmed: 26331761
J Clin Sleep Med. 2006 Apr 15;2(2):163-9
pubmed: 17557490
Diabet Med. 2006 May;23(5):469-80
pubmed: 16681555
Arch Intern Med. 2005 Apr 25;165(8):910-5
pubmed: 15851643
Ageing Res Rev. 2017 May;35:200-221
pubmed: 27702700
Health Qual Life Outcomes. 2007 Feb 27;5:12
pubmed: 17326844
Lancet. 2005 Apr 16-22;365(9468):1415-28
pubmed: 15836891
Public Health. 2016 Dec;141:26-31
pubmed: 27932012